Stabilized gp41 Structural Motif for HIV-1 Vaccine
HIV-1 疫苗的稳定 gp41 结构基序
基本信息
- 批准号:7284745
- 负责人:
- 金额:$ 25.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntibodiesAntigensBiomedical ResearchCaviaCoiled-Coil DomainConserved SequenceCysteineDevelopmentEpitopesGeneticGoalsHIV-1HIV-1 vaccineHelix (Snails)ImmunizationIndividualKnowledgeMembraneMolecular ConformationNumbersOryctolagus cuniculusParticulatePeptidesPropertyProteinsResearchSideStructureSurfaceThermodynamicsTodayVaccinationVariantdesigndimerdisulfide bondear helixhuman monoclonal antibodiesimmunogenicitynanoscaleneutralizing antibodynovelresponse
项目摘要
DESCRIPTION (provided by applicant): The development of immunogens capable of eliciting broadly neutralizing antibodies to HIV-1 remains one of the most difficult challenges confronting biomedical research today. Nonetheless, a small number of human monoclonal antibodies (mAbs) have been isolated from HIV-1-infected individuals that can neutralize primary isolates of HIV-1 from different genetic subtypes. Of these rare mAbs, two (2F5 and 4E10) recognize epitopes on the membrane-proximal region of the gp41 ectodomain. However, all attempts to elicit comparable anti-gp41 antibodies by vaccination with peptides or simple linear epitopes have thus far failed. Our approach to immunogen design is guided by our recent identification and structural determination of a novel two-stranded coiled-coil domain (C55) that includes the membrane-proximal epitope region of gp41. However, we have determined that the C55 dimer structure is too unstable to be suitable for immunogenicity studies. The overall goal of this research plan is to gain a detailed understanding of the structural and thermodynamic properties of the C55 coiled-coil domain, and to use this knowledge to design and produce stable immunogens for the elicitation of broadly neutralizing HIV-1 antibodies. Our central hypothesis is that presentation of the highly conserved sequences recognized by 2F5 and 4E10 in this new structural state opens a promising avenue for the discovery and development of novel immunogens to induce broadly reactive neutralizing antibodies. Specific aims of this research are: (1) To identify and develop stabilized versions of the C55 coiled-coil domain encompassing the 2F5 and 4E10 epitopes. We will identify and incorporate apolar side chain substitutions into the buried hydrophobic core of the dimer to stabilize the coiled-coil structure. We will also screen cysteine substitutions to introduce a disulfide bond between the two interacting helices. Our emphasis is to generate stable molecules that preserve both the dimer conformation and the critical surface-exposed residues of the membrane-proximal region. (2) To evaluate the immunological responses elicited by stabilized C55 coiled-coil variants in small animals. We will conduct immunogenicity studies in rabbits and guinea-pigs to determine whether the stabilized dimer structure can elicit neutralizing antibodies. These studies will involve immunization of the animals using soluble proteins. We will also evaluate the immunogenicity of the stable coiled-coil molecules captured onto nanometer-sized beads as particulate immunogens.
描述(由申请人提供):能够引发广泛中和 HIV-1 抗体的免疫原的开发仍然是当今生物医学研究面临的最困难的挑战之一。尽管如此,还是从 HIV-1 感染者中分离出了少量人单克隆抗体 (mAb),这些抗体可以中和来自不同遗传亚型的 HIV-1 初级分离株。在这些罕见的 mAb 中,有两种(2F5 和 4E10)可识别 gp41 胞外域近膜区域上的表位。然而,迄今为止,所有通过肽或简单线性表位疫苗接种来引发类似抗 gp41 抗体的尝试都失败了。我们的免疫原设计方法以我们最近对一种新型双链卷曲螺旋结构域 (C55) 的鉴定和结构测定为指导,该结构域包括 gp41 的近膜表位区域。然而,我们确定C55二聚体结构太不稳定,不适合免疫原性研究。该研究计划的总体目标是详细了解 C55 卷曲螺旋结构域的结构和热力学特性,并利用这些知识设计和生产稳定的免疫原,以引发广泛中和 HIV-1 抗体。我们的中心假设是,2F5 和 4E10 在这种新结构状态下识别的高度保守序列的呈现,为发现和开发新型免疫原以诱导广泛反应性中和抗体开辟了一条有希望的途径。这项研究的具体目标是: (1) 识别和开发包含 2F5 和 4E10 表位的 C55 卷曲螺旋结构域的稳定版本。我们将识别非极性侧链取代并将其合并到二聚体的埋藏疏水核心中,以稳定卷曲螺旋结构。我们还将筛选半胱氨酸取代,以在两个相互作用的螺旋之间引入二硫键。我们的重点是产生稳定的分子,既保留二聚体构象,又保留膜近端区域的关键表面暴露残基。 (2) 评估稳定的 C55 卷曲螺旋变体在小动物中引起的免疫反应。我们将在兔子和豚鼠中进行免疫原性研究,以确定稳定的二聚体结构是否可以引发中和抗体。这些研究将涉及使用可溶性蛋白质对动物进行免疫。我们还将评估捕获到纳米大小的珠子上作为颗粒免疫原的稳定卷曲螺旋分子的免疫原性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Min Lu其他文献
Min Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Min Lu', 18)}}的其他基金
Molecular Basis of Substrate Translocation in the Drug/H+ Antiporter 1 Family
药物/H 逆向转运蛋白 1 家族底物易位的分子基础
- 批准号:
10414517 - 财政年份:2022
- 资助金额:
$ 25.2万 - 项目类别:
Molecular Basis of Substrate Translocation in the Drug/H+ Antiporter 1 Family
药物/H 逆向转运蛋白 1 家族底物易位的分子基础
- 批准号:
10644018 - 财政年份:2022
- 资助金额:
$ 25.2万 - 项目类别:
Development of novel small-molecule inhibitors of HIV-1 fusion as microbicides
作为杀微生物剂的新型 HIV-1 融合小分子抑制剂的开发
- 批准号:
8892301 - 财政年份:2014
- 资助金额:
$ 25.2万 - 项目类别:
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens
用于 HIV-1 疫苗免疫原的工程包膜糖蛋白三聚体
- 批准号:
8743611 - 财政年份:2014
- 资助金额:
$ 25.2万 - 项目类别:
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides
gp41 介导融合的小分子抑制剂作为 HIV-1 局部杀菌剂
- 批准号:
8743614 - 财政年份:2014
- 资助金额:
$ 25.2万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8743609 - 财政年份:2014
- 资助金额:
$ 25.2万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8230476 - 财政年份:2011
- 资助金额:
$ 25.2万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8607113 - 财政年份:2011
- 资助金额:
$ 25.2万 - 项目类别:
Development of an HIV-1 entry inhibitor pre-drug as a microbicide
开发作为杀微生物剂的 HIV-1 进入抑制剂前药
- 批准号:
8112130 - 财政年份:2011
- 资助金额:
$ 25.2万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8704604 - 财政年份:2011
- 资助金额:
$ 25.2万 - 项目类别:
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
$ 25.2万 - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
$ 25.2万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
$ 25.2万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
$ 25.2万 - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
$ 25.2万 - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
$ 25.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
$ 25.2万 - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
$ 25.2万 - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
$ 25.2万 - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
$ 25.2万 - 项目类别:
Standard Grant